Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC — Stella

Home/ALK Positive Non-small Cell Lung Cancer/

View on ClinicalTrials.gov

Recruiting

Back to ALK Positive Non-small Cell Lung Cancer trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Guangdong Provincial Perople's Hospital, Guangzhou, Guangdong

Key details

Phase

Safety & dosing

Sponsor

Guangdong Association of Clinical Trials

Enrollment target

~126 participants

Started

August 2023

Primary completion

August 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated October 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.